• IBA - Regulated Information

    Source: Nasdaq GlobeNewswire / 09 Jan 2024 12:00:00   America/New_York

    IBA – TRANSPARENCY NOTIFICATION

    (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)

    Louvain-la-Neuve, Belgium, January 9th, 2024, 18:00

    Summary of the notification

    IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on January 5th 2024.

    In its notification, Vallcara Limited indicated that following an acquisition or disposal of securities or voting rights, its total shareholding in IBA SA had increased and its shareholding in IBA shares with voting rights had crossed the threshold of 1% on 02/01/2024.

    Content of the notification

    • Reason for the notification: Acquisition or disposal of securities or voting rights
    • Notification by: A person notifying alone

    A parent undertaking or a controlling person

    • Persons subject to the notification requirement:
    • Date on which the threshold is crossed: 02/01/2024
    • Threshold crossed (in %) : 1%
    • Denominator : 40.595.290
    • Notified details: (extract of the received notification form)
    • Full chain of controlled undertakings through which the holding is effectively held

    Vallcara Limited is 100% owned by Vallgesa Limited (C 58154), a company registered in Malta.

    • Additional information

    Vallcara Limited is receiving the shares from its sister company Solvanova Limited, as the latter is due to be liquidated in 2024. Vallcara Ltd. can exercise all the voting rights received from Solvanova Limited

    About IBA

    IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2.000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

    IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
    More information can be found at: www.iba-worldwide.com

    For further information, please contact:

    Valérie Van Impe
    Paralegal
    +32479267809
    legal@iba-group.com

     

     

    Attachment


Share on,